secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001213900-25-012510
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance
-------------------------------------------------------------------------

- Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.
- Net income $1.8M ($0.06 EPS) vs net loss of $3.3M ($0.14 loss) in prior year.
- Product gross margin improved to 58.9% from 27.2%; FY2025 product revenue outlook $8-10M reaffirmed.
- Regained Nasdaq compliance; debt-free with $1.1M cash and $4.1M working capital.
- OneRF placed in 5 epilepsy centers; FDA 510(k) submission for trigeminal nerve ablation expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/0001213900-25-012510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025012510/ea0230716-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-012510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer